A Phase 3 interventional study of Rabeprazole sodium 5 mg and Rabeprazole sodium 10 mg in Gastroesophageal Reflux, sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C.. Completed at 84 sites in 10 countries. Open to participants aged 1 Month to 11 Months. Per ClinicalTrials.gov, last updated 2013-05-22.
Sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 40 studies testing rabeprazole in Gastroesophageal Reflux — none open to participants now, none under way, none of them phase 3. Rabeprazole · Gastroesophageal Reflux.
Among the 40 studies testing rabeprazole in Gastroesophageal Reflux, this one is the 7th largest by enrollment of the 39 interventional ones that give a count, is one of 4 that started in 2009, is one of 16 in phase 3, and was the 31st registered.
1,215 studies on the registry are indexed under Gastroesophageal Reflux; 203 are open to participants now.
Browse Gastroesophageal Reflux studies →None of the 40 studies testing rabeprazole in Gastroesophageal Reflux is open now. The open studies under Gastroesophageal Reflux, anywhere →
Rabeprazole: first FDA approval 1999 (ACIPHEX). What it is approved for, and how studies give it, is on its page →
Of the 133 Gastroesophageal Reflux studies recruiting now, 57 (43%) set no upper age limit and 53 (40%) stop at 75 or younger; 22 take children under 18; 20 take healthy volunteers.
This study: 1 Month to 11 Months · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
40 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 5 · Phase 3 17 · Phase 4 8
First in 2001; this study’s year is marked. 4 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 344 is above the median of 68 across 799 interventional studies indexed under Gastroesophageal Reflux.
Median enrollment 100 across the 39 interventional studies. Of the 38 that completed or were terminated, 15 (39%) have results posted.
This tab as a report to print or save as PDF → With an account.
28 of 40 have an industry lead sponsor. The 10 most frequent:
This study is registered under Johnson & Johnson Pharmaceutical Research & Development, L.L.C., one of the names counted as Johnson & Johnson. Under that name alone:
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. is the lead sponsor of 465 studies on the registry; none are open to participants now.
27 studies in Gastroesophageal Reflux by Johnson & Johnson: none open now, 1 under way, none of them phase 3. Of 26 finished, 9 (35%) have results posted.
Among the 27 studies in Gastroesophageal Reflux by Johnson & Johnson, this one is the 3rd largest by enrollment of the 19 interventional ones that give a count, is one of 3 that started in 2009, is one of 4 in phase 3, and was the 14th registered.
Johnson & Johnson’s Gastroesophageal Reflux studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 40 studies testing rabeprazole in Gastroesophageal Reflux, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Johnson & Johnson’s 27 in Gastroesophageal Reflux:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess the effectiveness and safety of rabeprazole sodium, an inhibitor of gastric acid secretion of the protein pump inhibitor (PPI) class, compared with placebo in the treatment of gastrointestinal esophageal reflux disease (GERD) in infants 1 to 11 months of age.
Rabeprazole sodium belongs to the class of drugs known as proton pump inhibitors, which suppress gastric acid secretion. The drug is approved in the United States for the treatment of adults with GERD and other acid-related gastrointestinal disorders, and has been studied in adolescents (older than 12 years of age) with results similar to those in adults. However, the drug has not been studied in children under the age of 12 years. This study focuses on the efficacy and safety of rabeprazole sodium in infants aged 1 to 11 months, the pediatric group in which the prevalence of GERD-related symptoms is the greatest. This is a multicenter, double-blind, randomized, placebo-controlled, parallel-group withdrawal study to compare the efficacy and safety of 2 doses (0.5 mg/kg or 1.0 mg/kg daily) of rabeprazole with placebo in the treatment of infants aged 1 to 11 months who have a diagnosis of suspected GERD, symptomatic GERD, or endoscopically or histologically proven GERD. The study consists of 3 study periods: a screening period of up to 10 days, an open-label treatment period of up to 3 weeks, and a 5-week double-blind treatment period. Patients who have been receiving GERD therapy before screening will have their GERD therapy discontinued for 3 days before entering the open-label treatment period. Patients who have a positive clinical response according to the Clinical Global Impressions - Improvement (CGI-I) scale at the end of the first or second week of the open-label treatment period will enter the double-blind treatment period; those who do not will be withdrawn from the study. A parent, legal guardian, or other individual experienced in the care of the infant will be the primary caregiver, who is responsible for the daily and weekly assessments and study drug administration. Efficacy assessments consist of the Infant Gastroesophageal Reflux Questionnaire Revised (I GERQ-R) total score, the Infant Gastroesophageal Reflux Questionnaire-Daily Diary (I GERQ-DD) total score, the CGI-I, the Global Treatment Satisfaction Score, and the weight-for-age Z-score. Safety assessments include monitoring of concomitant therapies and adverse events throughout the study; clinical laboratory testing (hematology, clinical chemistry, urinalysis), measurement of vital signs (pulse and respiratory rate, blood pressure, temperature); and physical examination including length and weight. The study hypothesis is that rabeprazole sodium is superior to placebo in the treatment of GERD in infants aged 1 to 11 months. Rabeprazole sodium capsule(s) by mouth once a day, 10.0 milligram (mg)/kilogram (kg) for up to 3 weeks during the open-label treatment period and either 5.0 mg/kg or 10.0 mg/kg during the 5-week double-blind treatment period. To give the study drug to the infants, the contents of the capsule(s) are sprinkled onto a small amount of soft food or, as needed, the contents of the capsule(s) may be given in a small amount (5 milliliter [mL]) of infant formula or expressed breast milk.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Rabeprazole sodium 5 mg
Drug: Rabeprazole sodium 10 mg
Drug: Placebo
Rabeprazole Sodium 5 mg capsules once daily in the morning.
Rabeprazole Sodium 10 mg capsules once daily in the morning.
Matching placebo capsules once daily in the morning.
Change From Baseline in Average Daily Frequency of Regurgitation (Double-blind Phase/ Baseline Observation Carried Forward)
Time frame: Baseline, Week 8
Change From Baseline in Weight-for-Age Z-Score (Double-blind Phase/ Baseline Observation Carried Forward)
Body weight was measured with the participant unclothed and before a feeding during each office visit. In the analysis of weight data, weight will be transformed to the weight-for-age Z-score using World Health Organization Child Growth Standards, taking into account the infant's age and gender (Borghi E, 2006).
Time frame: Baseline, Week 8
Change From Baseline in I-GERQ-R Total Score (Double-blind Phase/ Baseline Observation Carried Forward)
The Infant Gastroesophageal Reflux Questionnaire-Revised (I-GERQ-R) is a 12-item questionnaire that is completed by the primary caregiver at every office or telephonic visit. It has a weekly recall and the items cover the frequency, amount and discomfort attributed to spit-up, refusal or stopping feeding, crying and fussing, hiccups, arching back and stopping breathing or changing color. The total score is calculated as the sum of all 12 scores for the individual questions, and ranges from 0 to 42. A higher value indicates a worse outcome.
Time frame: Baseline, Week 8
Change From Baseline in in Weekly Average I-GERQ-DD Total Score (Double-blind Phase/ Baseline Observation Carried Forward)
The Infant Gastroesophageal Reflux Questionnaire-Daily Diary (I-GERQ-DD) is a 9-item daily diary that the primary caregiver will be instructed to complete every evening at the same time interval after the participant has gone to sleep for the night. The I-GERQ-DD contains 3 subscales: the Regurgitation subscale, the Eating Behavior subscale and the Discomfort subscale. Each of the 9 items will be assigned a numeric score. The total score will be calculated as the sum of all 9 items, and ranges from 0 to 37. A higher value indicates a worse outcome.
Time frame: Baseline, Week 8
The Daily Average Number of Episodes Related to Each Volume of Regurgitation During the Double-blind Treatment Period
Time frame: Baseline, Week 8
Change From Baseline in Weekly Average I-GERQ-DD Regurgitation Subscale Score (Double-blind Phase/ Last Observation Carried Forward)
The Infant Gastroesophageal Reflux Questionnaire-Daily Diary (I-GERQ-DD) is a 9-item daily diary that the primary caregiver will be instructed to complete every evening at the same time interval after the participant has gone to sleep for the night. The I-GERQ-DD contains 3 subscales: the Regurgitation subscale, the Eating Behavior subscale and the Discomfort subscale. The Regurgitation subscale will be calculated as the sum of the 3 questions regarding regurgitation (Questions 1, 2, 3) and will range from 0 to 13. For each subscale score, a higher value indicates a worse outcome.
Time frame: Baseline, Week 8
Change From Baseline in Weekly Average I-GERQ-DD Discomfort Subscale Score (Double-blind Phase/ Last Observation Carried Forward)
The Infant Gastroesophageal Reflux Questionnaire-Daily Diary (I-GERQ-DD) is a 9-item daily diary that the primary caregiver will be instructed to complete every evening at the same time interval after the subject has gone to sleep for the night. The I-GERQ-DD contains 3 subscales: the Regurgitation subscale, the Eating Behavior subscale and the Discomfort subscale. The Discomfort subscale score will be calculated as the sum of the 3 questions regarding discomfort (Questions, 7, 8, 9) and will range from 0 to 12. For each subscale score, a higher value indicates a worse outcome.
Time frame: Baseline, Week 8
Change From Baseline in Weekly Average I-GERQ-DD Eating Behavior Subscale Score (Double-blind Phase/ Last Observation Carried Forward)
The Infant Gastroesophageal Reflux Questionnaire-Daily Diary (I-GERQ-DD) is a 9-item daily diary that the primary caregiver will be instructed to complete every evening at the same time interval after the subject has gone to sleep for the night. The I-GERQ-DD contains 3 subscales: the Regurgitation subscale, the Eating Behavior subscale and the Discomfort subscale. The Eating Behavior subscale score will be calculated as the sum of the 3 questions regarding eating behavior (Questions 4, 5, 6) and will range from 0 to 12. For each subscale score, a higher value indicates a worse outcome.
Time frame: Baseline, Week 8
| Milestone | Open-Label Rabeprazole Sodium 10 mg | Double-Blind Placebo | Double-Blind Rabeprazole Sodium 5 mg | Double-Blind Rabeprazole Sodium 10 mg |
|---|---|---|---|---|
| Started | 344 | 0 | 0 | 0 |
| Completed | 267 | 0 | 0 | 0 |
| Not completed | 77 | 0 | 0 | 0 |
| Withdrew: Adverse event | 4 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 20 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 1 | 0 | 0 | 0 |
| Withdrew: Protocol violation | 3 | 0 | 0 | 0 |
| Withdrew: Physician decision | 4 | 0 | 0 | 0 |
| Withdrew: Other | 45 | 0 | 0 | 0 |
| Milestone | Open-Label Rabeprazole Sodium 10 mg | Double-Blind Placebo | Double-Blind Rabeprazole Sodium 5 mg | Double-Blind Rabeprazole Sodium 10 mg |
|---|---|---|---|---|
| Started | 0 | 89 | 90 | 88 |
| Completed | 0 | 76 | 77 | 78 |
| Not completed | 0 | 13 | 13 | 10 |
| Withdrew: Adverse event | 0 | 6 | 2 | 3 |
| Withdrew: Withdrawal by subject | 0 | 6 | 5 | 2 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 2 |
| Withdrew: Other | 0 | 1 | 6 | 3 |
| frequency of Regurgitation | Double-Blind Placebo | Double-Blind Rabeprazole Sodium 5 mg | Double-Blind Rabeprazole Sodium 10 mg | Double-Blind Rabeprazole Sodium Total |
|---|---|---|---|---|
| Change From Baseline in Average Daily Frequency of Regurgitation (Double-blind Phase/ Baseline Observation Carried Forward) | -0.8 ± 1.58 | -0.8 ± 1.55 | -1.6 ± 3.63 | -1.2 ± 2.79 |
Body weight was measured with the participant unclothed and before a feeding during each office visit. In the analysis of weight data, weight will be transformed to the weight-for-age Z-score using World Health Organization Child Growth Standards, taking into account the infant's age and gender (Borghi E, 2006).
| Z-score | Double-Blind Placebo | Double-Blind Rabeprazole Sodium 5 mg | Double-Blind Rabeprazole Sodium 10 mg | Double-Blind Rabeprazole Sodium Total |
|---|---|---|---|---|
| Change From Baseline in Weight-for-Age Z-Score (Double-blind Phase/ Baseline Observation Carried Forward) | 0.11 ± 0.329 | 0.16 ± 0.322 | 0.11 ± 0.264 | 0.14 ± 0.295 |
| number of episodes | Double-Blind Placebo - Baseline | Double-Blind Rabeprazole Sodium 5 mg - Baseline | Double-Blind Rabeprazole Sodium 10 mg - Baseline | Double-Blind Placebo - Week 8 | Double-Blind Rabeprazole Sodium 5 mg - Week 8 | Double-Blind Rabeprazole Sodium 10 mg - Week 8 | Double-Blind Rabeprazole Sodium Total - Baseline | Double-Blind Rabeprazole Sodium Total - Week 8 |
|---|---|---|---|---|---|---|---|---|
| Less than 1 tablespoon | 1.2 ± 2.52 | 1.1 ± 1.49 | 1.9 ± 4.25 | 0.8 ± 2.15 | 0.7 ± 1.35 | 1.0 ± 1.92 | 1.5 ± 3.18 | 0.9 ± 1.66 |
| 1 to 2 tablespoons | 0.7 ± 1.04 | 0.7 ± 1.08 | 1.2 ± 1.73 | 0.5 ± 1.62 | 0.4 ± 0.75 | 0.7 ± 1.55 | 1.0 ± 1.45 | 0.6 ± 1.21 |
| More than 2 tablespoons to 2 fluid oz | 0.3 ± 0.53 | 0.2 ± 0.43 | 0.3 ± 0.77 | 0.2 ± 0.48 | 0.1 ± 0.60 | 0.2 ± 0.65 | 0.2 ± 0.62 | 0.2 ± 0.63 |
| More than 2 fluid oz to 4 fluid oz | 0.1 ± 0.19 | 0.0 ± 0.09 | 0.0 ± 0.08 | 0.0 ± 0.09 | 0.0 ± 0.14 | 0.0 ± 0.23 | 0.0 ± 0.08 | 0.0 ± 0.19 |
| More than 4 fluid oz | 0.0 ± 0.05 | 0.0 ± 0.14 | 0.0 ± 0.24 | 0.0 ± 0.11 | 0.0 ± 0.05 | 0.0 ± 0.04 | 0.0 ± 0.20 | 0.0 ± 0.04 |
The Infant Gastroesophageal Reflux Questionnaire-Daily Diary (I-GERQ-DD) is a 9-item daily diary that the primary caregiver will be instructed to complete every evening at the same time interval after the participant has gone to sleep for the night. The I-GERQ-DD contains 3 subscales: the Regurgitation subscale, the Eating Behavior subscale and the Discomfort subscale. The Regurgitation subscale will be calculated as the sum of the 3 questions regarding regurgitation (Questions 1, 2, 3) and will range from 0 to 13. For each subscale score, a higher value indicates a worse outcome.
| scores on a scale | Double-Blind Placebo | Double-Blind Rabeprazole Sodium 5 mg | Double-Blind Rabeprazole Sodium 10 mg | Double-Blind Rabeprazole Sodium Total |
|---|---|---|---|---|
| Change From Baseline in Weekly Average I-GERQ-DD Regurgitation Subscale Score (Double-blind Phase/ Last Observation Carried Forward) | -0.8 ± 2.57 | -0.8 ± 2.56 | -1.0 ± 2.38 | -0.9 ± 2.47 |
The Infant Gastroesophageal Reflux Questionnaire-Daily Diary (I-GERQ-DD) is a 9-item daily diary that the primary caregiver will be instructed to complete every evening at the same time interval after the subject has gone to sleep for the night. The I-GERQ-DD contains 3 subscales: the Regurgitation subscale, the Eating Behavior subscale and the Discomfort subscale. The Discomfort subscale score will be calculated as the sum of the 3 questions regarding discomfort (Questions, 7, 8, 9) and will range from 0 to 12. For each subscale score, a higher value indicates a worse outcome.
| scores on a scale | Double-Blind Placebo | Double-Blind Rabeprazole Sodium 5 mg | Double-Blind Rabeprazole Sodium 10 mg | Double-Blind Rabeprazole Sodium Total |
|---|---|---|---|---|
| Change From Baseline in Weekly Average I-GERQ-DD Discomfort Subscale Score (Double-blind Phase/ Last Observation Carried Forward) | 0.0 ± 2.24 | -0.1 ± 1.88 | -0.4 ± 1.94 | -0.2 ± 1.9 |
The Infant Gastroesophageal Reflux Questionnaire-Daily Diary (I-GERQ-DD) is a 9-item daily diary that the primary caregiver will be instructed to complete every evening at the same time interval after the subject has gone to sleep for the night. The I-GERQ-DD contains 3 subscales: the Regurgitation subscale, the Eating Behavior subscale and the Discomfort subscale. The Eating Behavior subscale score will be calculated as the sum of the 3 questions regarding eating behavior (Questions 4, 5, 6) and will range from 0 to 12. For each subscale score, a higher value indicates a worse outcome.
| scores on a scale | Double-Blind Placebo | Double-Blind Rabeprazole Sodium 5 mg | Double-Blind Rabeprazole Sodium 10 mg | Double-Blind Rabeprazole Sodium Total |
|---|---|---|---|---|
| Change From Baseline in Weekly Average I-GERQ-DD Eating Behavior Subscale Score (Double-blind Phase/ Last Observation Carried Forward) | -0.1 ± 2.54 | -0.1 ± 2.19 | -0.4 ± 2.15 | -0.3 ± 2.17 |
The Infant Gastroesophageal Reflux Questionnaire-Revised (I-GERQ-R) is a 12-item questionnaire that is completed by the primary caregiver at every office or telephonic visit. It has a weekly recall and the items cover the frequency, amount and discomfort attributed to spit-up, refusal or stopping feeding, crying and fussing, hiccups, arching back and stopping breathing or changing color. The total score is calculated as the sum of all 12 scores for the individual questions, and ranges from 0 to 42. A higher value indicates a worse outcome.
| scores on a scale | Double-Blind Placebo | Double-Blind Rabeprazole Sodium 5 mg | Double-Blind Rabeprazole Sodium 10 mg | Double-Blind Rabeprazole Sodium Total |
|---|---|---|---|---|
| Change From Baseline in I-GERQ-R Total Score (Double-blind Phase/ Baseline Observation Carried Forward) | -3.6 ± 6.41 | -3.8 ± 7.5 | -4.1 ± 7 | -3.9 ± 7.24 |
The Infant Gastroesophageal Reflux Questionnaire-Daily Diary (I-GERQ-DD) is a 9-item daily diary that the primary caregiver will be instructed to complete every evening at the same time interval after the participant has gone to sleep for the night. The I-GERQ-DD contains 3 subscales: the Regurgitation subscale, the Eating Behavior subscale and the Discomfort subscale. Each of the 9 items will be assigned a numeric score. The total score will be calculated as the sum of all 9 items, and ranges from 0 to 37. A higher value indicates a worse outcome.
| scores on a scale | Double-Blind Placebo | Double-Blind Rabeprazole Sodium 5 mg | Double-Blind Rabeprazole Sodium 10 mg | Double-Blind Rabeprazole Sodium Total |
|---|---|---|---|---|
| Change From Baseline in in Weekly Average I-GERQ-DD Total Score (Double-blind Phase/ Baseline Observation Carried Forward) | -1.9 ± 4.55 | -1.6 ± 4.85 | -2.1 ± 4.9 | -1.9 ± 4.86 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Open-Label Rabeprazole Sodium 10 mg | — | 15/344 (4.4%) | 116/344 (33.7%) |
| Double-Blind Placebo | — | 2/89 (2.2%) | 33/89 (37.1%) |
| Double-Blind Rabeprazole Sodium 5 mg | — | 8/90 (8.9%) | 34/90 (37.8%) |
| Double-Blind Rabeprazole Sodium 10 mg | — | 3/88 (3.4%) | 32/88 (36.4%) |
| Event | Open-Label Rabeprazole Sodium 10 mg | Double-Blind Placebo | Double-Blind Rabeprazole Sodium 5 mg | Double-Blind Rabeprazole Sodium 10 mg |
|---|---|---|---|---|
| GastroenteritisInfections and infestations | 2/344 | 0/89 | 2/90 | 0/88 |
| Upper Respiratory Tract InfectionInfections and infestations | 2/344 | 0/89 | 2/90 | 0/88 |
| Urinary Tract InfectionInfections and infestations | 2/344 | 0/89 | 2/90 | 0/88 |
| BronchiolitisInfections and infestations | 1/344 | 0/89 | 0/90 | 1/88 |
| Viral InfectionInfections and infestations | 1/344 | 0/89 | 0/90 | 1/88 |
| Beta 2 Microglobulin IncreasedInvestigations | 1/344 | 0/89 | 0/90 | 1/88 |
| HypoacusisEar and labyrinth disorders | 1/344 | 1/89 | 0/90 | 0/88 |
| Failure to ThriveMetabolism and nutrition disorders | 2/344 | 1/89 | 0/90 | 0/88 |
| PyrexiaGeneral disorders | 1/344 | 0/89 | 1/90 | 0/88 |
| AgitationPsychiatric disorders | 1/344 | 0/89 | 1/90 | 0/88 |
| Event | Open-Label Rabeprazole Sodium 10 mg | Double-Blind Placebo | Double-Blind Rabeprazole Sodium 5 mg | Double-Blind Rabeprazole Sodium 10 mg |
|---|---|---|---|---|
| PyrexiaGeneral disorders | 22/344 | 5/89 | 9/90 | 6/88 |
| Upper Respiratory Tract InfectionInfections and infestations | 19/344 | 6/89 | 3/90 | 8/88 |
| DiarrhoeaGastrointestinal disorders | 21/344 | 7/89 | 8/90 | 4/88 |
| NasopharyngitisInfections and infestations | 19/344 | 4/89 | 8/90 | 3/88 |
| Blood Gastrin IncreasedInvestigations | 10/344 | 0/89 | 2/90 | 7/88 |
| Gastrooesophageal Reflux DiseaseGastrointestinal disorders | 13/344 | 7/89 | 2/90 | 4/88 |
| VomitingGastrointestinal disorders | 13/344 | 5/89 | 6/90 | 2/88 |
| ConstipationGastrointestinal disorders | 15/344 | 4/89 | 2/90 | 5/88 |
| Otitis MediaInfections and infestations | 14/344 | 4/89 | 5/90 | 3/88 |
| RashSkin and subcutaneous tissue disorders | 12/344 | 4/89 | 5/90 | 2/88 |
| Age Continuous(months) | Open-Label Rabeprazole Sodium 10 mg |
|---|---|
| Mean | 4.6 ± 2.55 |
| Sex: Female, Male(Participants) | Open-Label Rabeprazole Sodium 10 mg |
|---|---|
| Female | 139 |
| Male | 205 |
| Region of Enrollment(participants) | Open-Label Rabeprazole Sodium 10 mg |
|---|---|
| AUSTRALIA | 7 |
| BELGIUM | 11 |
| BULGARIA | 24 |
| HUNGARY | 51 |
| ISRAEL | 36 |
| ITALY | 5 |
| NETHERLANDS | 9 |
| POLAND | 56 |
| SOUTH AFRICA | 12 |
| UNITED STATES | 133 |
| AgeCategorical(participants) | Open-Label Rabeprazole Sodium 10 mg |
|---|---|
| >= 1 to < 4 Months | 175 |
| >= 4 to < 8 Months | 124 |
| >= 8 to < 12 Months | 45 |
The record gives a start of Nov 2009, a primary completion of Nov 2011 and a completion of Nov 2011. It does not say whether these dates are actual or estimated.
Results were first posted in May 2013, 1 year 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Rabeprazole
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. →